SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi LLC is trending as investors react to a significant convertible notes offering and news that Siemens turbines have arrived for its major data center project, fueling community speculation about a looming anchor tenant deal. While some traders express frustration with the company's capital-intensive nature and governance questions, others view the recent price volatility and institutional stake-building as a prime re-entry opportunity for a long-term AI infrastructure play.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending as investors react to positive expansion momentum, analyst buy ratings, and anticipation surrounding upcoming earnings. The community is actively debating the company's valuation, potential relisting prospects, and its competitive stance against rivals in both domestic and international markets.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

United States Oil Fund (USO) is experiencing high volatility as the market reacts to conflicting reports of diplomatic negotiations versus escalating military tensions in the Strait of Hormuz. Community discussion is heavily focused on the disconnect between official administration statements about potential peace deals and the ongoing supply-chain disruptions, with many investors debating whether to hedge against further geopolitical instability or capitalize on sharp price swings driven by algorithmic trading.

Ambarella, Inc. engages in the development of low-power system-on-a-chip (SoC), semiconductors, and software for edge artificial intelligence (AI) applications and intelligent automation. The firm's products include video security, advanced driver assistance (ADAS), electronic mirror, drive recorder, driver or cabin monitoring, autonomous driving, and other robotics applications. It operates through the following geographical segments: Taiwan, Asia Pacific, Europe, North America, and United States. The company was founded by Feng Ming Wang and Leslie D. Kohn on January 15, 2004 and is headquartered in Santa Clara, CA.

Ambarella Inc

Ambarella shares are surging as investors react to reports of potential acquisition interest from NXP Semiconductors, a move seen as a strategic play to bolster NXPs automotive and edge AI portfolio. While the market remains cautious due to the lack of a finalized deal and recent volatility in the semiconductor sector, the community is actively debating the potential takeover premium and the company's long-term strength as a specialist in edge AI vision chips.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpool is facing significant market volatility as investors weigh disappointing earnings results, a surprise dividend suspension, and ongoing strategic shifts aimed at aggressive debt reduction. Community sentiment is deeply divided, with many traders discussing potential bankruptcy risks while contrarian investors speculate on long-term value opportunities amid the stock's multi-year lows.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly is experiencing extreme volatility and a significant selloff despite reporting record revenue and raised guidance, leaving the community divided between those viewing the price drop as a buying opportunity and those concerned about the company's growth narrative. Investors are actively debating whether the stock's recent price compression is a fundamental re-rating or a temporary overreaction that sets the stage for a potential rebound.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors react to the companys strategic repurchase of convertible debt and high-stakes anticipation surrounding potential near-term milestone payments and upcoming European regulatory news. The community is actively discussing these de-risking maneuvers against a backdrop of ongoing short interest, with many speculating that the company is clearing its balance sheet ahead of major commercial catalysts or a potential acquisition.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is experiencing renewed investor interest and upward momentum driven by the successful EU approval of its oral Wegovy pill, which is positioned to challenge competitors by removing the need for injections. The market is actively weighing the company's strong early adoption data against ongoing legal maneuvers with Eli Lilly, while long-term investors remain focused on the company's manufacturing scale and its potential to capture a larger share of the expanding obesity and diabetes treatment market.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune is facing significant volatility as investors digest highly critical FDA briefing documents ahead of an upcoming advisory committee meeting, with regulators questioning the effectiveness and data integrity of the firm's melanoma therapy. The community is sharply divided, with many traders anticipating a third rejection while others remain focused on the potential for a regulatory upset driven by patient advocacy pressure.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending amid intense community speculation regarding the company's valuation, upcoming earnings expectations, and the impact of the new CEO transition. Investors are actively debating the firm's long-term potential in Duchenne muscular dystrophy treatments compared to competitors, while expressing frustration over the stock's price action and persistent short interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$CVKD  #NASDAQ Cadrenal Therapeutics: A Paradigm Shift in HIT Treatment. https://www.youtube.com/watch?v=4UcqG2DwjEs

Cadrenal Therapeutics: A Paradigm Shift in HIT Treatment · Jul 15, 2026 The provided sources detail late-breaking Phase 2 clinical trial results for CAD-1005, a first-in-class medication developed by Cadrenal Therapeutics to treat Heparin-Induced Thrombocytopenia (HIT). Although the study did not meet its primary endpoint regarding platelet recovery, it demonstrated a clinically significant 25% reduction in thrombotic events compared to a placebo.